



## **Diquafosol (tetrasodium)**

**Catalog No: tcsc6370** 

Available Sizes
Size: 5mg
Size: 10mg
Size: 50mg
Size: 100mg
Specifications
CAS No: 211427-08-6
<b>Formula:</b> $C_{18}^{H}_{22}^{N}_{4}^{Na}_{4}^{O}_{23}^{P}_{4}$
Pathway: GPCR/G Protein
Target: P2Y Receptor
Purity / Grade: >98%
<b>Solubility:</b> H2O : ≥ 32 mg/mL (36.44 mM)
Alternative Names: INS365
Observed Molecular Weight: 878.23





## **Product Description**

Diquafosol tetrasodium is a **P2Y2** receptor agonist that stimulates fluid and mucin secretion on the ocular surface, as a topical treatment of dry eye disease.

*In Vitro:* Cell viability significantly decreased after treatment with 30% diluted diquafosol for 1 hour and 6 hours after treatment with 10% and 20% diluted diquafosol. Twenty-four hours after wounding monolayers, 3% diquafosol, and 0.3% HCECs exhibits significantly more wound healing than the control<sup>[1]</sup>.

In Vivo: In a rat dry eye model, the P2Y2 agonist diquafosol tetrasodium is found to improve surface health, based on increases in tear fluid secretion, corneal epithelial resistance, and release of glycoprotein-containing moieties from goblet cells. Beginning at 2 weeks and continuing for an additional 2 weeks, maximal declines in dye penetrance of approximately 50% occurred with doses of diquafosol tetrasodium as low as  $1\%^{[2]}$ . INS365 significantly suppresses corneal damage at concentrations of more than  $0.1\% \text{ w/v}^{[3]}$ .

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!